1 Title

- 2 A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-
- 3 CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with
- 4 centralized assays across healthcare facilities in the United States

5

6 Authors

- 7 Elissa M. Robbins^{a#}
- 8 Rasa Bertuzis^a
- 9 Ho-Chen Chiu^b
- 10 Lupe Miller^a
- 11 Christopher Noutsios^a
- 12

13 Affiliations

- 14 ^aRoche Molecular Systems, Inc., Pleasanton, California, USA
- 15 ^bRoche Sequencing Solutions, Inc., Indianapolis, Indiana, USA
- 16

17 **#Corresponding author**

- 18 Elissa M. Robbins
- 19
- 20 Running title
- 21 POC SARS-CoV-2 & Influenza A/B test

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Non-structured abstract

23 Respiratory diseases can share many of the same symptoms, highlighting the need for 24 timely and accurate differentiation to facilitate effective clinical management and reduce 25 transmission. Compared with centralized testing, molecular point-of-care tests (POCT) can 26 provide a faster time to result. 27 We evaluated the RT-PCR POCT Cobas[®] SARS-CoV-2 & Influenza A/B gualitative assay for 28 use on the Cobas Liat® system (the POC SARS-CoV-2 & Influenza A/B test) in nasal and 29 nasopharyngeal swab samples from 10 diverse healthcare facilities in the US. A composite 30 comparator design consisting of three centralized tests was used to analyze SARS-CoV-2, 31 whilst performance versus a single centralized test was used for analysis of influenza A and 32 B. Evaluations included performance stratified by sample type (prospective/retrospective and 33 nasal/nasopharyngeal [paired by subject]), collection method (self/healthcare worker-34 collected [alternated and approximately balanced], symptom status 35 (symptomatic/asymptomatic), and SARS-CoV-2 vaccination status, as well as assay 36 inclusivity and system ease of use. 37 A total of 2,247 samples were tested. For SARS-CoV-2, the overall percent agreement (OPA) 38 was 98.8% (95% CI: 97.9, 99.3) in nasal swab samples and 99.0% (95% CI: 98.2, 99.4) in 39 nasopharyngeal swab samples. Regression analysis showed that Ct values from paired nasal 40 and nasopharyngeal swab samples were highly correlated (correlation coefficient 0.83). The 41 OPA was \geq 99.5% (sample type dependent) and 100.0% for influenza A and B, respectively. 42 The POC SARS-CoV-2 & Influenza A/B test was easy to use. 43 These results support the use of the POCT in various sample types and by various operators

44 in the intended-use setting.

45 **Summary statement/importance**

This study highlights the benefits of RT-PCR POCT, namely comparable performance to centralized testing in multiple sample types and ease of use. Utilizing assays such as the POC SARS-CoV-2 & Influenza A/B test may improve timely differentiation of respiratory diseases that share similar symptoms.

50 Introduction

51 More than 4 years since the start of the coronavirus disease 2019 (COVID-19) pandemic,

52 much of the world has returned to normality, yet COVID-19 continues to cause severe illness

and mortality in the United States (US) and elsewhere(1, 2). This applies particularly for the

54 immunocompromised, who are at risk of severe outcomes (3) and comprise approximately

55 3% of the US adult population(4). Disease activity is year-round, but seasonal spikes occur

56 from November to April(5), coinciding with circulation of other respiratory viruses, such as

57 influenza(6). Respiratory diseases such as COVID-19 and influenza share similar

58 symptoms(7), highlighting the need for timely and accurate differentiation of the causative

agent to help facilitate effective clinical management and reduce onward transmission.

60 The current choice of testing for severe acute respiratory syndrome coronavirus 2 (SARS-61 CoV-2) is setting dependent(8), but standard laboratory-based (i.e., centralized) nucleic acid 62 amplification tests are the mainstay of diagnosis(9). Numerous antigen or molecular point-63 of-care tests (POCT) are commercially available(10, 11), offering the benefit of a faster time 64 to result(12). Both POCT formats have lower performance compared with centralized 65 testing, particularly sensitivity (13) — a secondary analysis of antigen POCT found the 66 performance to be commonly lower than stated within manufacturers' instructions for use 67 (14) — but molecular POCT have relatively higher performance in comparison with antigen 68 POCT, with pooled sensitivity values of 93% (99% specificity) versus 71% (99% specificity), 69 respectively(13). Molecular POCT can provide actionable results in as little as 20 minutes 70 depending on the assay and workflow(11).

71 Influenza is a significant cause of severe illness and death(15-17), resulting in a substantial 72 clinical burden to patients and the healthcare system alike(18). Molecular POCT for the 73 detection of influenza A/B subtypes, and other respiratory viruses such as respiratory 74 syncytial virus, have been available for several years(11, 12, 19-22). Clinical practice 75 quidelines from the Infectious Diseases Society of America recommend that antivirals are 76 initiated for certain patient groups as soon as possible regardless of illness duration, or 77 within 48 hours of illness onset(23), supporting the use of rapid molecular POCT for influenza testing in preference to centralized laboratory testing. In the hospital setting, an 78 79 interventional study of a molecular POCT for influenza found significant improvements in 80 isolation practices and reductions in length of stay compared with centralized testing(24), whilst a modeling study found that the introduction of POCT could reduce time to diagnosis, 81 82 hospital stay, and in-hospital costs(25). Molecular POCT for influenza can generate 83 sensitivity estimates of \geq 96–100% in real-world settings(22, 26). 84 The primary objective of this study was to evaluate the real-world clinical performance of 85 the POC Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat 86 system (herein referred to as the POC SARS-CoV-2 & Influenza A/B), a multiplexed RT-PCR 87 test combining measurement of SARS-CoV-2 and influenza subtypes, in reference to 88 comparator centralized PCR tests for SARS-CoV-2 and influenza A and B viruses. Sample 89 types were nasal and nasopharyngeal swab specimens from individuals suspected of 90 respiratory viral infection consistent with COVID-19, and asymptomatic individuals exposed

to COVID-19, who presented at healthcare facilities across the US during the COVID-19
public health emergency. Secondary objectives were to evaluate the influence of collection
method and the ease of use of the Cobas Liat system.

94 Materials and methods

95 **Sites**

96 Testing was conducted at 11 sites: 10 geographically diverse healthcare facilities that were

- 97 representative of intended-use sites (i.e., POC settings, such as emergency departments,
- 98 urgent care, pediatric and primary care clinics, and drive-through COVID-19 testing sites),
- 99 and one reference laboratory for centralized testing. After testing using the POC SARS-CoV-2
- 100 & Influenza A/B test at the healthcare facilities, samples were shipped to the reference
- 101 laboratory for analysis with the comparator assays (see below).

102 Healthcare facilities were selected based on sample availability, ability to provide adequate

103 resources and operators, ability to adhere to good clinical practice, and with the aim of

104 ensuring representation of the demographic diversity of the US population. Not all

105 healthcare facilities performing testing were certified under Clinical Laboratory Improvement

106 Amendments (CLIA) regulations to perform waived testing, but all facilities met the

107 requirements for CLIA-waived settings (i.e., intended-use settings using untrained non-

108 laboratory personnel). All healthcare facilities performed both sample collection and POC

109 testing. POC operators at the 10 healthcare facilities (n=30 operators in total) had limited or

110 no laboratory training and were representative of typical test operators in CLIA-waived

111 settings (e.g., nurses, nursing assistants, and medical assistants). Operators at the

112 reference laboratory were blinded to the results generated at the healthcare facilities.

113 Study population

The symptomatic group comprised samples from individuals with suspected respiratory viral infection consistent with COVID-19 (see Signs/symptoms, Supplementary material). The asymptomatic group comprised individuals with self-reported 'recent' exposure (timeframe undefined) to SARS-CoV-2-positive individuals or any other reasons to suspect COVID-19. Patient clinical information was gathered, including, but not limited to, antiviral usage for up

- to 7 days prior to and on the day of sample collection, gender, race/ethnic group, and age.
- 120 Individuals presenting at the healthcare facilities were considered for study inclusion,
- subject to the eligibility criteria (see Eligibility criteria, Supplementary material).

122 Study design

- 123 The clinical performance of the POC SARS-CoV-2 & Influenza A/B test (27) was evaluated by
- 124 comparing results to a composite comparator method for the SARS-CoV-2 analyte using the
- 125 following three highly sensitive centralized testing assays: Cobas SARS-CoV-2 qualitative
- assay for use on the Cobas 6800/8800 systems (herein referred to as the 6800/8800 SARS-

127 CoV-2 test)(28); Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas

- 128 6800/8800 systems (herein referred to as the 6800/8800 SARS-CoV-2 & Influenza A/B
- 129 test)(29); and Hologic[®] Aptima[®] SARS-CoV-2 Assay(30).
- 130 The clinical performance for the influenza A/B analyte components of the POC SARS-CoV-2
- 131 & Influenza A/B test was evaluated against a single centralized testing assay, the 6800/8800
- 132 SARS-CoV-2 & Influenza A/B (29).
- 133 Samples that generated invalid results were repeated where sample volume permitted
- additional testing; samples generating a second invalid result upon retesting were reported
- as invalid. Interrogation of discrepant samples was not performed, though selected samples
- 136 were further retested with the POC SARS-CoV-2 & Influenza A/B test for exploratory
- 137 purposes.

138 Sample types and collection

- 139 Sample types included fresh and frozen nasal and nasopharyngeal swab samples, collected
- 140 in the same media formulations but under different brand names: Copan Universal
- 141 Transport Medium (UTM) or BD Universal Viral Transport (UVT) medium.

142 Prospective fresh samples (UTM)

143 One nasal swab and one nasopharyngeal swab sample were collected from each study 144 participant. A nasal swab of both nostrils was first collected either by the healthcare worker (HCW), herein referred to as 'HCW-collected', or by the study participant under instruction 145 146 from the HCW, herein referred to as 'self-collected', as per manufacturer's instructions.(31) 147 A nasopharyngeal swab was then collected by HCWs from the same study participant to generate paired samples. If a nasopharyngeal swab had already been collected (using one 148 149 nostril) as part of the healthcare facility's standard of care, the study nasopharyngeal swab 150 was taken from the opposite nostril. 151 All prospective samples were collected from patients presenting to healthcare facilities 152 during February to June 2022, characteristic of the 2021/2022 winter respiratory season. Retrospective frozen samples (archived or purchased from external vendors; UTM or UVT) 153 154 The low influenza prevalence in the prospective population was anticipated because of 155 reduced international travel, new respiratory care paradigms, increased public health 156 awareness, and use of interventions (such as masking policies or social distancing) that 157 occurred during the COVID-19 pandemic and study enrollment period, in which influenza A 158 virus had been the dominant virus type in circulation.(32) Therefore, frozen samples positive 159 for influenza A virus and for influenza B virus were used to supplement the prospectively 160 collected fresh samples. These retrospective samples were collected in the US during the 161 2013–2014, 2014–2015, and 2019–2020 influenza seasons. Baseline demographic data and 162 patient characteristics related to these samples were unavailable. 163 Retrospective samples with known SARS-CoV-2 status, collected between March 29, 2021

and May 26, 2021, were also included in the SARS-CoV-2 analyses.

Whilst multiple freeze-thaw cycles have a limited effect on the viral titer(33), there is the potential for samples that were initially low-titer positives to appear negative following storage. Internal Roche data support the stability of viral titer for up to three freeze-thaw cycles, so retrospective samples were only eligible for inclusion if they had undergone no more than two freeze-thaw cycles. Retrospective positive and negative samples were blended in a standard POCT workflow and assessed alongside prospectively collected samples.

172 Details of assays and instruments

173 POC SARS-CoV-2 & Influenza A/B test (POC RT-PCR)

174 The Cobas Liat analyzer is for *in vitro* diagnostic use(27). The analyzer automates all nucleic

acid amplification test processes, including target enrichment, inhibitor removal, nucleic acid

176 extraction, reverse transcription, DNA amplification, real-time detection, and result

177 interpretation in approximately 20 minutes(27). The Cobas Liat system comprises the Cobas

178 Liat analyzer in conjunction with the Cobas Liat assay tubes(27).

179 The POC SARS-CoV-2 & Influenza A/B test utilizes a single-use disposable assay tube that

180 contains all the reagents necessary for the detection of SARS-CoV-2 and hosts the sample

181 preparation and PCR processes(34). This multiplex real-time RT-PCR test is intended for the

182 simultaneous rapid *in vitro* qualitative detection and differentiation of SARS-CoV-2, influenza

183 A, and influenza B virus RNA in healthcare provider-collected nasal and nasopharyngeal

swab samples and self-collected nasal swab samples (collected in a healthcare setting with

185 instruction by a healthcare provider) from individuals suspected of respiratory viral infection

186 consistent with COVID-19(34).

187 <u>6800/8800 SARS-CoV-2 & Influenza A/B test (centralized testing method [CTM] 1)</u>

The Cobas 6800/8800 systems consist of the sample supply module, the transfer module, the processing module, and the analytic module(29). Automated data management is performed by the Cobas 6800/8800 software, which assigns results for all tests. Results are available within less than 3.5 hours after loading the sample on the system.(29) The positive SARS-CoV-2 result is defined as positive on the SARS-CoV-2 channel (Target 2) and/or the pan-sarbeco channel (Target 3).

194 The 6800/8800 SARS-CoV-2 & Influenza A/B test is an automated multiplex real-time RT-

195 PCR assay intended for simultaneous qualitative detection and differentiation of SARS-CoV-

196 2, influenza A virus, and/or influenza B virus RNA in healthcare provider-collected nasal and

197 nasopharyngeal swab samples and self-collected nasal swab samples (collected in a

198 healthcare setting with instruction by a healthcare provider) from individuals suspected of

199 respiratory viral infection consistent with COVID-19(29).

200 <u>6800/8800 SARS-CoV-2 test (CTM 2)</u>

201 The 6800/8800 SARS-CoV-2 test is an automated real-time RT-PCR assay intended for the 202 gualitative detection of nucleic acids from SARS-CoV-2 in healthcare provider-instructed, 203 self-collected anterior nasal (nasal) swab samples (collected onsite) and healthcare provider-204 collected nasal, nasopharyngeal, and oropharyngeal swab samples collected from any 205 individuals, including those suspected of COVID-19 by their healthcare provider, and those 206 without symptoms or with other reasons to suspect COVID-19(28). The positive SARS-CoV-2 207 result is defined as positive on the SARS-CoV-2 channel (Target 1) and/or the pan-sarbeco 208 channel (Target 2).

209 <u>Hologic Aptima SARS-CoV-2 assay (tiebreaker; CTM 3)</u>

As a commonly used molecular assay(30), CTM 3 was utilized as a tiebreaker. The test utilizes transcription-mediated amplification for the qualitative detection of RNA from SARS-CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal swab samples, nasopharyngeal wash/aspirate, or nasal aspirates obtained from individuals meeting COVID-19 clinical and/or epidemiological criteria(35).

215 Analyses

216 All data analyses were performed using SAS/STAT[®] software (v9.4 or higher of the SAS

217 System for Linux). No formal sample size calculations were calculated for this study, but

218 patient enrollment was adjusted to accommodate disease prevalence and to generate a

219 minimum of 50 SARS-CoV-2 positives, 30 influenza A positives, and 10 influenza B positives

220 for analysis.

221 The clinical performance of the POC SARS-CoV-2 & Influenza A/B test was evaluated using

222 estimates of positive percent agreement (PPA), negative percent agreement (NPA), and

223 overall percent agreement (OPA), calculated with 2-sided 95% confidence intervals (CI)

using the Wilson-score method(36). Comparison was against either the composite

225 comparator for SARS-CoV-2 (CTM 1, CTM 2, and CTM 3 [tiebreaker if required]) or a single

226 comparator for influenza A/B (CTM 1).

227 For SARS-CoV-2, concordant results from CTM 1 and CTM 2 established true positive or true

negative status. In the event of discordance between CTM 1 and CTM 2, CTM 3 (the

tiebreaker) was used to establish true status. Samples could be coded as uninterpretable in

the event of invalid, failed, aborted or missing results that were not resolved upon retesting.

231 If CTM 1 or CTM 2 or CTM 3 returned uninterpretable results, and the other two methods

232 returned different results (i.e., CTM 1 positive, CTM 2 negative, and CTM 3

uninterpretable), then the status of the sample would be described as indeterminate.

234 McNemar's mid-p test (P-value) was used to assess any differences between sample types.

A P-value of <0.05 was considered statistically significant.

- 236 POCT operators were asked to complete a questionnaire to evaluate the ease of use of the
- 237 POC SARS-CoV-2 & Influenza A/B test.

238 In silico analysis of the POC SARS-CoV-2 & Influenza A/B test was performed to assess

assay design inclusivity on all available SARS-CoV-2 sequences (taxonomy ID 2697049) in

240 the Global Initiative on Sharing All Influenza Data (GISAID) and National Center for

241 Biotechnology Information (NCBI) databases up to July 2024 (>16,800,000 sequences in

242 NCBI and >8,900,000 sequences in GISAID). The predicted impact of each variant on gene

target 1 and gene target 2 primer and probe binding site sequence was evaluated using

244 Roche proprietary software and Melting5 software. A SARS-CoV-2 sequence would be

potentially not detected by the POC SARS-CoV-2 & Influenza A/B test if a delay in cycle

threshold greater than five cycles and/or a probe melting temperature of <65°C was

247 predicted.

248 Ethics statement

249 This study was a non-interventional evaluation of an *in vitro* diagnostic device (test results 250 were not used to inform patient care decisions). This study was conducted in compliance 251 with International Conference on Harmonisation Good Clinical Practice guidelines, 252 regulations of the US Food and Drug Administration (FDA), and the Declaration of Helsinki. 253 The study protocol was submitted to Institutional Review Boards (IRBs) in accordance with 254 FDA and local regulatory requirements before the start of the study. The following IRBs gave permission for this study to be performed: NorthShore University Health System 255 256 Institutional Review Board; University of Rochester, Research Subjects Review Board; and 257 Western IRB.

258 Results

259 Participants and summary of testing results

- 260 Subjects from 10 geographically diverse healthcare facilities were enrolled in the study. The
- summary of testing results can be seen in **Supplemental Table A**. A total of 2,209 SARS-
- 262 CoV-2 results from prospective samples (both nasal and nasopharyngeal swabs) were valid
- 263 for inclusion in downstream analyses.

264 **Population and baseline characteristics**

- 265 Baseline demographic data for study participants were available for the prospectively
- collected samples; details on the study participants are presented in **Table 1**. Of these
- subjects, 506 were male (47.8%) and 553 were female (52.2%). The median age was 35
- 268 years (range 0–86).
- 269 Patient characteristics are present in **Supplemental Table B**. In total, 60.4% of subjects in
- the prospective population had signs and symptoms of respiratory infection, with days from
- onset of first symptom ranging from 1 to 365 days. The remaining 39.6% of subjects were
- asymptomatic but were clinically suspected of SARS-CoV-2 infection by their healthcare
- 273 provider due to recent exposure or other reason. The nasal swab samples were evenly
- 274 distributed between HCW-collected and self-collected.

275 Medical history

- 276 The medical history relating to vaccination status is presented in **Table 2**. Most participants
- 277 received a COVID-19 vaccine (68.7%), with Pfizer as the most common vaccine for both first
- and second doses (69.5% and 72.2%, respectively).

279 SARS-CoV-2

- 280 Determination of the composite comparator status for SARS-CoV-2
- 281 In symptomatic study participants, the composite comparator method was SARS-CoV-2
- positive for 134 nasal and 131 nasopharyngeal swab samples (**Supplemental Table C**).

In asymptomatic study participants, the composite comparator method was SARS-CoV-2

positive for 39 nasal and 39 nasopharyngeal swab samples (**Supplemental Table C**).

285 <u>Performance</u>

286 The total number of samples that were positive, negative, or invalid, and how these align

with the composite comparator status, can be seen in **Figure 1**. The diagnostic

288 performance (total number of positive and negative results) for SARS-CoV-2 can be seen in

289 **Table 3**. Agreement between the composite comparator and the POC SARS-CoV-2 &

290 Influenza A/B test for detection of SARS-CoV-2 in nasal swabs (total, prospective and

291 retrospective, self-collected or HCW-collected), nasopharyngeal swabs (total, prospective

and retrospective), in samples from vaccinated and unvaccinated participants, and in

symptomatic and asymptomatic participants can be seen in **Supplemental Table D**. For

294 nasal swab samples, the total OPA, PPA, and NPA was 98.8% (95% CI: 97.9, 99.3), 97.1%

295 (95% CI: 93.3, 98.7), and 99.1% (95% CI: 98.2, 99.5), respectively. Of note, the OPA for

296 HCW-collected nasal swab samples was 98.4% (95% CI: 97.0, 99.2) and 99.1% (95% CI:

297 98.0, 99.6) for self-collected nasal swab samples. The total OPA, PPA, and NPA for

298 nasopharyngeal swab samples was 99.0% (95% CI: 98.2, 99.4), 96.4% (95% CI: 92.4,

299 98.4), and 99.4% (95% CI: 98.7, 99.8), respectively.

300 Using all paired results for nasal and nasopharyngeal swab samples by subject, the swab

301 type did not make a difference in the reported result (McNemar's mid-p test, P=0.771).

302 Cycle threshold (Ct) value distributions

303 The range of Ct values in nasal and nasopharyngeal swab samples can be seen in **Figure 2**.

304 Self-collected nasal swabs showed the highest average viral load followed by

305 nasopharyngeal swabs, then HCW-collected nasal swabs.

306 The range of Ct values in subject-paired nasal and nasopharyngeal swab samples can be

- 307 seen in **Figure 3**. The Deming regression analysis showed that the two sample types were
- highly correlated (**Figure 3A**; r = 0.83). Exploration of the collection method showed that
- 309 HCW-collected nasal swabs had greater concordance between the paired samples (Figure
- **310 3B**; r = 0.91) than the self-collected nasal swabs (r = 0.77; **Figure 3C**).

311 Discordance

- 312 Fourteen nasal and 11 nasopharyngeal swab samples showed discordant results between
- 313 the POC SARS-CoV-2 & Influenza A/B test and the centralized testing methods
- 314 (Supplemental Table E); 10 were positive only on the POC SARS-CoV-2 & Influenza A/B
- 315 test.
- 316 Influenza A
- 317 Performance
- 318 The agreement between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800
- 319 SARS-CoV-2 & Influenza A/B test for detection of influenza A in nasopharyngeal swabs
- 320 (total, prospective and retrospective) and nasal swabs (total, prospective and retrospective,
- 321 HCW-collected or self-collected) can be seen in **Supplemental Table F**. The OPA ranged
- 322 from 98.9% to 100.0%.
- 323 Discordance
- 324 Two nasal and five nasopharyngeal swab samples showed discordant results between the
- 325 POC SARS-CoV-2 & Influenza A/B test and the 6800/8800 SARS-CoV-2 & Influenza A/B test
- 326 for detection of influenza A (**Supplemental Table G**), four of which were positive only on
- 327 the POC SARS-CoV-2 & Influenza A/B test.

328 Influenza B

329 <u>Performance</u>

- 330 The agreement between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800
- 331 SARS-CoV-2 & Influenza A/B test for detection of influenza B in nasopharyngeal swabs
- 332 (total, prospective and retrospective) and nasal swabs (total, prospective and retrospective,
- 333 self-collected nasal or HCW-collected) can be seen in **Supplemental Table H**. The OPA for
- all comparisons was 100.0%.

335 Discordance

- No discordant results between the POC SARS-CoV-2 & Influenza A/B test and the 6800/8800
- 337 SARS-CoV-2 & Influenza A/B test for detection of influenza B were recorded.

338 Evaluation of the ease of use for the Cobas Liat system

Twenty-seven operators with experience of testing samples on the Cobas Liat completed the questionnaire. The operators' average scores indicating their agreement with the statements in the questionnaire are shown in **Supplemental Table I**. The overall score was 4.5 out of 5 for the operators' answers to all eight statements, indicating that the operators agreed that the Cobas Liat system was easy to use.

344 Inclusivity analysis

- 345 The POC SARS-CoV-2 & Influenza A/B test targets the nucleocapsid (N) and ORF1a/b
- regions of the SARS-CoV-2 genome.(34) In silico analysis showed that 99.98% of NCBI and
- 347 99.99% of GISAID sequences for SARS-CoV-2 had no changes in the primer/probe binding
- 348 sites of both target regions simultaneously. All sequences were predicted to be detected by
- 349 at least one of the two sites.
- 350 Discussion

351 In this study, we evaluated the performance of the POC SARS-CoV-2 & Influenza A/B test 352 against up to three centralized assays, stratified by various parameters. The high 353 performance of the POC SARS-CoV-2 & Influenza A/B test in comparison with centralized 354 testing methods utilizing nasopharyngeal or nasal samples has previously been reported(37-355 41), but this study is the first to report the performance of the POC SARS-CoV-2 & Influenza 356 A/B test across variables such as collection method (self/HCW, retrospective/prospective), 357 vaccination status, symptom status, and ease of use. Using the comparator result to 358 establish the status of infection, we found high agreement between the POC RT-PCR test 359 and the centralized testing assays for all three analytes across all variables. 360 Previously, a meta-analysis of nucleic acid amplification testing reported that the sensitivity 361 for detection of SARS-CoV-2 in nasal samples may be less than nasopharyngeal 362 samples(42), whilst a study specifically assessing the POC SARS-CoV-2 & Influenza A/B test 363 reported similar differences in SARS-CoV-2 detection by sample type(37). However, we saw 364 no evidence of a sample-type difference in sensitivity, with SARS-CoV-2 positivity identified 365 in both nasal and nasopharyngeal swab samples to a similar extent (POC SARS-CoV-2 & 366 Influenza A/B test positivity rate approximately 15%; the difference in sensitivity [nasal 367 minus nasopharyngeal] was +0.9%).

368 A small study from Denmark found almost equivalent sensitivity for detection of SARS-CoV-2 369 using self- and HCW-collected samples (84.2% vs 89.5%, respectively), and that patients 370 preferred self-collection(43). In our study, whether nasal samples were collected by HCWs 371 or by the patients themselves had little impact on the agreement values between the POC 372 RT-PCR test and the comparators. Indeed, in all comparisons the agreement for self-373 collected samples was actually higher than for HCW-collected samples. For SARS-CoV-2, Ct 374 values of paired nasal and nasopharyngeal swab samples as measured by the POC RT-PCR 375 test were highly correlated, and Ct values were on average lower in nasal swab samples 376 (i.e., higher viral RNA titer) compared with nasopharyngeal swab samples, with self-

377 collected nasal swabs exhibiting the lowest Ct values. Collectively, this indicates that the
378 high performance level of the POC RT-PCR test is maintained across collection methods, and
379 that patients are able to self-sample effectively, and are willing to do so.

380 We identified a small number of discrepant samples for the SARS-CoV-2 analyte in both 381 nasal and nasopharyngeal swab samples, consistent with other studies(37, 38), most of 382 which were false positives. The majority of the false positives were in the high Ct/low viral 383 titer range (POC SARS-CoV-2 & Influenza A/B test Ct values: lowest 28.2, median 35.2, 384 highest 37.1) and thus close to or at the lower limit of detection of Ct 35.2 (USA-WA1/2020 385 strain) for the POC SARS-CoV-2 & Influenza A/B test(34). Of the false negatives detected by 386 the POC SARS-CoV-2 & Influenza A/B test, all except one sample were in the high Ct range. 387 Indeed, after exploratory re-testing of false-negative nasopharyngeal samples, two were 388 found to be positive (re-tested Ct values were 34.8 and 35.4). Generally, low viral burden 389 can be a cause of discrepant results(44), and a small external quality assessment 390 (reproducibility) study reported that the performance of the POC SARS-CoV-2 & Influenza 391 A/B test is highest at low Ct values(45).

392 US legislation categorizes tests for complexity (moderate or high) using seven criteria, such 393 as the need for training and experience, and assigns scores within each criterion(45). Test 394 systems can be assigned as 'waived complexity' under certain conditions, and these tests 395 require no formal operator training or competency(45). In addition to CLIA-certified 396 laboratories, the POC SARS-CoV-2 & Influenza A/B test is authorized for use in patient care 397 settings that are CLIA waived(34). In conjunction with the fast turnaround offered by the 398 Cobas Liat system and demonstrated in studies of the POC SARS-CoV-2 & Influenza A/B test 399 in real-world settings (40, 46) or studies evaluating workflow or processing time(41, 47), our 400 study confirms that the POC SARS-CoV-2 & Influenza A/B test is easy to use in CLIA-waived 401 settings, and offers results in a timeframe conducive for rapid patient management.

402 The strength of our multicenter study lies in the comprehensive nature of the variables 403 assessed, encompassing a wide variety of patient characteristics likely to be encountered in 404 healthcare settings. The study included a prospectively enrolled cohort of patients seeking 405 care, which is representative of the intended-use population of the POC SARS-CoV-2 & 406 Influenza A/B test. Our study has some limitations. Firstly, we did not ascertain the SARS-407 CoV-2 variants present in the samples. Whilst the emergence of SARS-CoV-2 variants has 408 the ability to affect the diagnostic performance of the test, previous studies have indicated 409 that the POC SARS-CoV-2 & Influenza A/B test detects both wild-type and variants of 410 concern, such as Alpha (B.1.1.7) or Omicron (B.1.1.529)(39, 47). Bioinformatic analysis to 411 assess inclusivity showed that the POC SARS-CoV-2 & Influenza A/B test is predicted to bind 412 all sequences available in the NCBI and GISAID databases as of July 2024. The dual target 413 assay design helps to ensure that the assay is robust and safeguards against the emergence 414 of variants that have the potential to affect assay performance and evade detection.

415 Conclusion

416 A POC RT-PCR test combining both measurement of SARS-CoV-2 and influenza subtypes 417 with performance equivalent to routine centralized testing would provide a critical tool to 418 improve the diagnosis and management of COVID-19 and influenza. We found that the 419 performance of the POC SARS-CoV-2 & Influenza A/B test was comparable to centralized 420 testing methods. With the ease of use and equivalent performance, it highlights the question 421 as to whether centralized testing should be considered as the gold standard. A study of the 422 POC Cobas Influenza A/B test (a Liat RT-PCR test that detects only the influenza analyte) in 423 the emergency department found that POC testing for influenza was useful in improving 424 several metrics, including the indication for treatment with neuraminidase in positive 425 cases(48). It is relevant to note that SARS-CoV-2 and influenza coinfection can increase the 426 risk of severe outcomes compared with those infected with SARS-CoV-2 alone, particularly 427 for those coinfected with influenza A.(49) Our study highlights the benefits of molecular

- 428 multiplex POCT to help improve timely differentiation of respiratory diseases that share
- 429 similar symptoms and support efforts to improve patient management.

430 Funding

431 This study was funded by Roche Molecular Systems, Inc (Pleasanton, California, USA).

432 Disclosures

- 433 EMR, RB, HC, LM, and CN are employees of Roche Molecular Systems, Inc. EMR participates
- 434 in Roche Connect and is a shareholder.

435 Assay disclaimers

- 436 The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system
- 437 (herein referred to as the POC SARS-CoV-2 & Influenza A/B test) was originally approved
- 438 under Emergency Use Authorization EUA201779 and has since been cleared and Clinical
- 439 Laboratory Improvement Amendments (CLIA) waived under 223591/CW220014,
- 440 respectively, in the US and is CE-IVD marked in the European Union. Sample collection in
- the patient's home is not approved in the US or European Union.
- 442 The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800
- 443 systems (herein referred to as the 6800/8800 SARS-CoV-2 & Influenza A/B test) is
- 444 authorized only for use under Emergency Use Authorization (EUA) in the US, and is CE-IVD
- 445 marked in the European Union. The assay is not approved for use in asymptomatic patients
- in the US or European Union. The assay is not approved for use as a point-of-care (POC)
- 447 test/near-patient test (NPT) in the US/European Union. Sample collection in the patient's
- 448 home is not approved in the US or European Union.

The Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein

- 450 referred to as the 6800/8800 SARS-CoV-2 test) is authorized only for use under EUA in the
- 451 US, and is CE-IVD marked in the European Union. The assay is not approved for use as a

- 452 POC test/NPT in the US/European Union. Sample collection in the patient's home is not
- 453 approved in the US or European Union.
- 454 Hologic Aptima SARS-CoV-2 assay is an FDA EUA assay.(30)

455 Data availability

- 456 The datasets generated during and/or analyzed during the current study are not publicly
- 457 available due to patient confidentiality. Any access requests from qualified researchers
- 458 should be submitted directly to the Ethical Committee of each participating study site.

459 Acknowledgments

- 460 Medical writing support was provided by Corrinne Segal of Obsidian Healthcare Group Ltd
- 461 (London, UK) and was funded by Roche Molecular Systems, Inc.
- 462 COBAS and LIAT are trademarks of Roche. All other product names and trademarks are the

463 property of their respective owners.

- 464 We would like to thank Saima Shams and Vaishali Mody for their contributions to the
- 465 development of the Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the
- 466 Cobas Liat system (herein referred to as the POC SARS-CoV-2 & Influenza A/B test), and
- 467 Jingtao Sun for his bioinformatics expertise.

468 **Figures**

469 Figure 1: Detection of SARS-CoV-2 using the POC SARS-CoV-2 & Influenza A/B test and the composite comparator (prospective and

470 retrospective, symptomatic and asymptomatic subjects)^a



472 Abbreviations: CC, composite comparator; POC RT-PCR, point-of-care RT-PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

- 473 aThe composite comparator comprises the 6800/8800 SARS-CoV-2 & Influenza A/B test, 6800/8800 SARS-CoV-2 test, and Hologic® Aptima®
- 474 SARS-CoV-2 Assay; the POC RT-PCR test is the POC SARS-CoV-2 & Influenza A/B test.
- 475 The Cobas[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat[®] system is herein referred to as the POC SARS-CoV-2 &
- 476 Influenza A/B test. The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems is herein referred to as
- 477 the 6800/8800 SARS-CoV-2 & Influenza A/B test. Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems is herein
- 478 referred to as the 6800/8800 SARS-CoV-2 test.



- 481 Abbreviations: Ct, cycle threshold; HCW, healthcare worker-collected; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
- 482 ^aFalse positives are represented by black circles. Cross represents mean Ct values. Nasal (total): n=179, mean Ct 23.1, median Ct 21.9,
- 483 minimum Ct 11.0, maximum Ct 36.8; HCW-collected nasal: n=87, mean Ct 23.9, median Ct 23.7, minimum Ct 12.3, maximum Ct 36.8; self-
- 484 collected nasal: n=92, mean Ct 22.4, median Ct 21.1, minimum Ct 11.0, maximum Ct 36.1; nasopharyngeal: n=177, mean Ct 23.4, median Ct
- 485 22.8, minimum Ct 10.6, maximum Ct 37.1.

486 False positives are indicated by black circles. The Cobas[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat[®] system is

487 herein referred to as the POC SARS-CoV-2 & Influenza A/B test. Horizontal solid line represents median values. Upper and lower boundaries of

488 box plot represent 75th and 25th percentile.

490 Figure 3: Deming regression for the SARS-CoV-2 analyte from the POC SARS-CoV-2 & Influenza A/B test in subject-paired nasal and

- 491 <u>nasopharyngeal swab samples</u>^a
- 492 A: Nasal (total); B: HCW-collected nasal swab; C: Self-collected nasal swab



- 494 Abbreviations: Ct, cycle threshold; FP, false positive; HCW, healthcare worker-collected; NPS, nasopharyngeal swab; NS, nasal; NS FP, nasal 495 false positive; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
- ⁴⁹⁶ ^aThe Cobas[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat[®] system is herein referred to as the POC SARS-CoV-2 &
- 497 Influenza A/B test. Prospective symptomatic = open circle; prospective exposed = triangle. Dashed line represents perfect correlation. Solid
- 498 line represents Deming regression. Red data points represent HCW-collected nasal swabs. Blue data points represent self-collected nasal
- 499 swabs.

500 Tables

501 <u>Table 1: Demographics (prospective symptomatic and asymptomatic subjects)</u>

Characteristics	Prospective population		
Total			
Ν	1,059		
Age (years)			
Mean	34.2		
Standard deviation	19.88		
Median	35.0		
Range (minimum–maximum) ^a	0.0-86.0		
Age group (years), n (%)			
≤18	287 (27.1)		
19–39	319 (30.1)		
40–64	391 (36.9)		
≥65	62 (5.9)		
Sex at birth, n (%)	I		
Male	506 (47.8)		
Female	553 (52.2)		
Ethnicity, n (%)			
Hispanic/Latino	212 (20.0)		
Not Hispanic/not Latino	589 (55.6)		
Not reported ^b	236 (22.3)		
Unknown ^c	22 (2.1)		
Race, n (%)			
American Indian/Alaskan Native	3 (0.3)		
Asian	37 (3.5)		
Black/African American	175 (16.5)		
Native Hawaiian/Pacific Islander	6 (0.6)		
White	520 (49.1)		
Other	56 (5.3)		
Not reported ^b	262 (24.7)		

- ^aAll subjects <1 year old are counted as age 0.
- ^bA clinical site that was a mobile drive-through site was not able to collect race/ethnicity
- 505 identification from subjects.
- ⁵⁰⁶ ^cUnknown category indicates subjects for whom the corresponding information is not
- 507 available.

509 <u>Table 2: Subject medical history (prospective symptomatic and asymptomatic subjects)</u>

Characteristics	Population statistics
Total	
N	1,059
Subject received the influenza vaccine within the last	6 weeks, n (%)
Yes	14 (1.3)
No	1,045 (98.7)
Unknown	0 (0.0)
Influenza vaccine route of administration, n (%) ^a	
Intramuscular	14 (100.0)
Intranasal	0 (0.0)
Unknown	0 (0.0)
Subject received a COVID-19 vaccine, n (%)	
Yes	728 (68.7)
No	303 (28.6)
Unknown	28 (2.6)
Type of COVID-19 vaccine received for first dose, n (%	(o) ^b
Pfizer	506 (69.5)
Moderna	185 (25.4)
Johnson & Johnson (J & J)	30 (4.1)
Other	3 (0.4)
Unknown	4 (0.5)
Type of COVID-19 vaccine received for second dose, n	(%) ^b
Pfizer	488 (72.2)
Moderna	182 (26.9)
Other	3 (0.4)
Unknown	3 (0.4)
Type of COVID-19 vaccine received first booster, n (%) ^{b,c}
Pfizer	217 (64.0)
Moderna	115 (33.9)
Johnson & Johnson (J & J)	5 (1.5)

Characteristics	Population statistics		
Other	1 (0.3)		
Unknown	1 (0.3)		

511

- 512 Abbreviations: COVID-19, coronavirus disease 2019
- 513 ^aPercentages calculated based on number of subjects who received the influenza vaccine
- 514 within the last 6 weeks prior to enrollment and sample collection.
- 515 ^bPercentages calculated based on number of subjects who received COVID-19 vaccine or
- 516 first booster.
- 517 ^cThere were six subjects that reported receiving a second booster.

518

520 Table 3: Results for the detection of SARS-CoV-2 using the composite comparator compared with the POC SARS-CoV-2 & Influenza A/B testa

	Composite comparator (+)	Composite comparator (-)	Total	PPA % (95% CI)	NPA % (95% CI)
Nasal					
POC SARS-CoV-2 &	165	9	174	97.1 (93.3, 98.7)	99.1 (98.2, 99.5)
Influenza A/B test					
(+)					
POC SARS-CoV-2 &	5	961	966		
Influenza A/B test (-)					
Total	170	970	1,140		
Nasopharyngeal					
POC SARS-CoV-2 &	162	5	167	96.4 (92.4, 98.4)	99.4 (98.7, 99.8)
Influenza A/B test					
(+)					
POC SARS-CoV-2 &	6	896	902		
Influenza A/B test (-)					
Total	168	901	1,069		

521

522 Abbreviations: CI, Score confidence interval; NPA, negative percent agreement; PPA, positive percent agreement; SARS-CoV-2, severe acute

523 respiratory syndrome coronavirus 2.

³The Cobas[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat[®] system is herein referred to as the POC SARS-CoV-2 &

525 Influenza A/B test.

526 References

527	1.	Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, Macdonald
528		B, Dattani S, Beltekian D, Ortiz-Ospina E, Roser M. 2020. Coronavirus
529		pandemic (COVID-19). https://ourworldindata.org/coronavirus. Accessed Mar
530		06, 2024.
531	2.	Ahmad FB, Cisewski JA, Xu J, Anderson RN. 2023. COVID-19 Mortality Update
532		- United States, 2022. MMWR Morb Mortal Wkly Rep 72:493–496.
533	3.	Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. 2023. Clinical course
534		and management of COVID-19 in the era of widespread population immunity.
535		Nat Rev Microbiol 22:75–88.
536	4.	Antinori A, Bausch-Jurken M. 2023. The burden of COVID-19 in the
537		immunocompromised patient: implications for vaccination and needs for the
538		future. J Infect Dis 228:S4–S12.
539	5.	Wiemken TL, Khan F, Puzniak L, Yang W, Simmering J, Polgreen P, Nguyen
540		JL, Jodar L, McLaughlin JM. 2023. Seasonal trends in COVID-19 cases,
541		hospitalizations, and mortality in the United States and Europe. Sci Rep
542		13:3886.
543	6.	Moriyama M, Hugentobler WJ, Iwasaki A. 2020. Seasonality of Respiratory
544		Viral Infections. Annu Rev Virol 7:83–101.
545	7.	World Health Organization. 2024. Coronavirus disease (COVID-19):
546		similarities and differences between COVID-19 and influenza.
547		https://www.who.int/news-room/questions-and-answers/item/coronavirus-
548		disease-covid-19-similarities-and-differences-with-influenza. Accessed Aug 05,
549		2024.

550	8.	Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, Dos Santos
551		Ferreira CE, Tateda K, Van Der Pol B. 2022. Choice of SARS-CoV-2 diagnostic
552		test: challenges and key considerations for the future. Crit Rev Clin Lab Sci
553		59:445–459.
554	9.	Hayden MK, Hanson KE, Englund JA, Lee MJ, Loeb M, Lee F, Morgan DJ, Patel
555		R, El Mikati IK, Iqneibi S, Alabed F, Amarin JZ, Mansour R, Patel P, Falck-Ytter
556		Y, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. 2023. The
557		Infectious Diseases Society of America guidelines on the diagnosis of
558		coronavirus disease 2019 (COVID-19): molecular diagnostic testing. Clin
559		Infect Dis doi:10.1093/cid/ciad646.
560	10.	Katzenschlager S, Brümmer LE, Schmitz S, Tolle H, Manten K, Gaeddert M,
561		Erdmann C, Lindner A, Tobian F, Grilli M, Pollock NR, Macé A, Erkosar B,
562		Carmona S, Ongarello S, Johnson CC, Sacks JA, Denkinger CM, Yerlikaya S.
563		2023. Comparing SARS-CoV-2 antigen-detection rapid diagnostic tests for
564		COVID-19 self-testing/self-sampling with molecular and professional-use
565		tests: a systematic review and meta-analysis. Sci Rep 13:21913.
566	11.	Tolan NV, Horowitz GL. 2022. Clinical diagnostic point-of-care molecular
567		assays for SARS-CoV-2. Clin Lab Med 42:223–236.
568	12.	Shirley JD, Bennett SA, Binnicker MJ. 2023. Current regulatory landscape for
569		viral point-of-care testing in the United States. J Clin Virol 164:105492.
570	13.	Fragkou PC, Moschopoulos CD, Dimopoulou D, Ong DSY, Dimopoulou K,
571		Nelson PP, Schweitzer VA, Janocha H, Karofylakis E, Papathanasiou KA,
572		Tsiordras S, De Angelis G, Thölken C, Sanguinetti M, Chung HR, Skevaki C.
573		2023. Performance of point-of care molecular and antigen-based tests for

574 SARS-CoV-2: a living systematic review and meta-analysis. Clin Microbiol 575 Infect 29:291–301.

- Bigio J, MacLean EL, Das R, Sulis G, Kohli M, Berhane S, Dinnes J, Deeks JJ,
 Brümmer LE, Denkinger CM, Pai M. 2023. Accuracy of package inserts of
 SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus
 systematic review data. Lancet Microbe 4:e875–e882.
- 580 15. Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, Omer SB,
- 581 Abbas Q, Ali A, Amu A, Azziz-Baumgartner E, Bassat Q, Abdullah Brooks W,
- 582 Chaves SS, Chung A, Cohen C, Echavarria M, Fasce RA, Gentile A, Gordon A,
- 583 Groome M, Heikkinen T, Hirve S, Jara JH, Katz MA, Khuri-Bulos N, Krishnan A,
- 584 de Leon O, Lucero MG, McCracken JP, Mira-Iglesias A, Moïsi JC, Munywoki PK,
- 585 Ourohiré M, Polack FP, Rahi M, Rasmussen ZA, Rath BA, Saha SK, Simões EA,
- 586 Sotomayor V, Thamthitiwat S, Treurnicht FK, Wamukoya M, Yoshida LM, Zar
- 587 HJ, Campbell H, Nair H. 2020. Global burden of respiratory infections
- associated with seasonal influenza in children under 5 years in 2018: a
- 589 systematic review and modelling study. Lancet Glob Health 8:e497–e510.
- 590 16. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J,
- 591 Simonsen L, Viboud C. 2019. Global mortality associated with seasonal
- 592 influenza epidemics: new burden estimates and predictors from the GLaMOR
- 593 Project. J Glob Health 9:020421.
- 594 17. GBD 2017 Influenza Collaborators. 2019. Mortality, morbidity, and
 595 hospitalisations due to influenza lower respiratory tract infections, 2017: an
 596 analysis for the Global Burden of Disease Study 2017. Lancet Respir Med
 597 7:69–89.

598	18.	Maleki F, Welch V, Lopez SMC, Cane A, Langer J, Enstone A, Markus K,
599		Wright O, Hewitt N, Whittle I. 2023. Understanding the global burden of
600		influenza in adults aged 18-64 years: a systematic literature review from 2012
601		to 2022. Adv Ther 40:4166–4188.
602	19.	Gibson J, Schechter-Perkins EM, Mitchell P, Mace S, Tian Y, Williams K, Luo R,
603		Yen-Lieberman B. 2017. Multi-center evaluation of the Cobas ${\mathbb R}$ Liat ${\mathbb R}$
604		Influenza A/B & RSV assay for rapid point of care diagnosis. J Clin Virol 95:5–
605		9.
606	20.	Young S, Phillips J, Griego-Fullbright C, Wagner A, Jim P, Chaudhuri S, Tang
607		S, Sickler J. 2020. Molecular point-of-care testing for influenza A/B and
608		respiratory syncytial virus: comparison of workflow parameters for the ID
609		Now and Cobas Liat systems. J Clin Pathol 73:328–334.
610	21.	Azar MM, Landry ML. 2018. Detection of influenza A and B viruses and
611		respiratory syncytial virus by use of Clinical Laboratory Improvement
612		Amendments of 1988 (CLIA)-waived point-of-care assays: a paradigm shift to
613		molecular tests. J Clin Microbiol 56:e00367-18.
614	22.	Melchers WJG, Kuijpers J, Sickler JJ, Rahamat-Langendoen J. 2017. Lab-in-a-
615		tube: real-time molecular point-of-care diagnostics for influenza A and B using
616		the Cobas® Liat® system. J Med Virol 89:1382–1386.
617	23.	Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein
618		S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL,
619		McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. 2019. Clinical practice
620		guidelines by the Infectious Diseases Society of America: 2018 update on

621		diagnosis, treatment, chemoprophylaxis, and institutional outbreak
622		management of seasonal influenza. Clin Infect Dis 68:895–902.
623	24.	Berry L, Lansbury L, Gale L, Carroll AM, Lim WS. 2020. Point of care testing of
624		Influenza A/B and RSV in an adult respiratory assessment unit is associated
625		with improvement in isolation practices and reduction in hospital length of
626		stay. J Med Microbiol 69:697–704.
627	25.	Rahamat-Langendoen J, Groenewoud H, Kuijpers J, Melchers WJG, van der
628		Wilt GJ. 2019. Impact of molecular point-of-care testing on clinical
629		management and in-hospital costs of patients suspected of influenza or RSV
630		infection: a modeling study. J Med Virol 91:1408–1414.
631	26.	Mikamo H, Koizumi Y, Yamagishi Y, Asai N, Miyazono Y, Shinbo T, Horie M,
632		Togashi K, Robbins EM, Hirotsu N. 2022. Comparing the Cobas Influenza A/B
633		Nucleic acid test for use on the Cobas Liat System (Liat) with rapid antigen
634		tests for clinical management of Japanese patients at the point of care. PLoS
635		One 17:e0276099.
636	27.	Roche Molecular Systems Inc. 2021. Cobas® Liat® System User Guide.
637	28.	Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-
638		2. Qualitative assay for use on the Cobas® 6800/8800 Systems. P/N:
639		09179917001-07EN.
640	29.	Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-
641		2 & Influenza A/B. Qualitative assay for use on the Cobas® 6800/8800
642		Systems. P/N: 09233474190.

- 30. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. 2020.
- 644 Comparison of the analytical sensitivity of seven commonly used commercial
- 645 SARS-CoV-2 automated molecular assays. J Clin Virol 130:104578.
- 646 31. Copan Diagnostics Inc. 2020. Instructions for use. FLOQSwabs. HPC217
- 647 Rev.00 Date 2020.10. https://www.copanusa.com/wp-
- 648 content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf.
- 649 Accessed Aug 5, 2024.
- 650 32. Centers for Disease Control and Prevention. 2023. 2021-2022 flu season
- 651 summary. https://www.cdc.gov/flu/season/faq-flu-season-2021-
- 652 2022.htm#print. Accessed Aug 05, 2024.
- 33. Dzung A, Cheng PF, Stoffel C, Tastanova A, Turko P, Levesque MP, Bosshard
- 654 PP. 2021. Prolonged unfrozen storage and repeated freeze-thawing of SARS-
- 655 CoV-2 patient samples have minor effects on SARS-CoV-2 detectability by RT-
- 656 PCR. J Mol Diagn 23:691–697.
- 657 34. Roche Molecular Systems Inc. 2020. Instructions for use. Cobas® SARS-CoV-
- 658 2 & Influenza A/B. Nucleic acid test for use on the Cobas® Liat® System.
- 659 P/N: 09211101190.
- 660 35. Hologic. 2020. Instructions for use. Aptima® SARS-CoV-2 Assay (Panther®661 System).
- 662 36. Wilson E. 1927. Probable inference, the law of succession, and statistical
 663 inference. J Am Stat Assoc 22:209–212.
- Akashi Y, Horie M, Kiyotaki J, Takeuchi Y, Togashi K, Adachi Y, Ueda A,
 Notake S, Nakamura K, Terada N, Kurihara Y, Kiyasu Y, Suzuki H. 2022.

666 Clinical performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in

nasal samples. Mol Diagn Ther 26:323–331.

- 668 38. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF,
- Jin R, Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical
- 670 performance of the point-of-care Cobas Liat for detection of SARS-CoV-2 in 20
- 671 minutes: a multicenter study. J Clin Microbiol 59:e02811-20.
- 67239.Park K, Sung H, Kim MN. 2023. Evaluation of the cobas Liat detection test for
- 673 SARS-CoV-2 and influenza viruses following the emergence of the SARS-CoV-
- 2 Omicron variant. Diagn Microbiol Infect Dis 105:115891.
- 40. Er TK, Chou YC, Chen SY, Huang JW. 2021. Rapid cobas Liat SARS-CoV-2
- assay in comparison with the laboratory-developed real-time RT-PCR test. ClinLab 67.
- 41. Matic N, Lawson T, Ritchie G, Lowe CF, Romney MG. 2024. Testing the limits
- of multiplex respiratory virus assays for SARS-CoV-2 at high cycle threshold
- values: Comparative performance of Cobas 6800/8800 SARS-CoV-2 &
- 681 Influenza A/B, Xpert Xpress SARS-CoV-2/Flu/RSV, and Cobas Liat SARS-CoV-2
- 682 & Influenza A/B. J Assoc Med Microbiol Infect Dis Can 8:328-335.
- 42. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021.
- 684 Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2
- 685 molecular detection: a systematic review and meta-analysis. J Clin Microbiol686 59:e02881-20.
- 43. Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB,
- 688 Thudium RF, Kirkby NS, Raaschou-Pedersen DET, Bundgaard JS, Iversen K,
- 689 Bundgaard H, Todsen T. 2020. Self-collected versus healthcare worker-

- 690 collected swabs in the diagnosis of severe acute respiratory syndrome
- coronavirus 2. Diagnostics 10:678.
- 692 44. Craney AR, Velu PD, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, La Spina
- 693 M, Lei B, Chen A, Alston T, Rozman A, Loda M, Rennert H, Cushing M,
- 694 Westblade LF. 2020. Comparison of two high-throughput reverse
- 695 transcription-PCR systems for the detection of severe acute respiratory
- 696 syndrome coronavirus 2. J Clin Microbiol 58:e00890-20.
- 45. Buchta C, Zeichhardt H, Badrick T, Coucke W, Wojtalewicz N, Griesmacher A,
- 698 Aberle SW, Schellenberg I, Jacobs E, Nordin G, Schweiger C, Schwenoha K,
- Luppa PB, Gassner UM, Wagner T, Kammel M. 2023. Classification of "near-
- 700 patient" and "point-of-care" SARS-CoV-2 nucleic acid amplification test
- 701 systems and a first approach to evaluate their analytical independence of
- 702 operator activities. J Clin Virol 165:105521.
- 46. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. 2023. A study to assess
- the impact of the Cobas point-of-care RT-PCR assay (SARS-CoV-2 and
- 705 Influenza A/B) on patient clinical management in the emergency department
- of the University of California at Davis Medical Center. J Clin Virol

707 168:105597.

- 708 47. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW, Li SY, Hsieh SS, Liu
- 709 MT, Yang JR, Tang SH, Perng CL, Chang FY, Shang HS. 2021. Clinical
- comparison of three sample-to-answer systems for detecting SARS-CoV-2 in
- 711 B.1.1.7 lineage emergence. Infect Drug Resist 14:3255–3261.

- 712 48. Perlitz B, Slagman A, Hitzek J, Riedlinger D, Möckel M. 2021. Point-of-care
- testing for influenza in a university emergency department: a prospective
- study. Influenza Other Respir Viruses 15:608–617.
- 715 49. Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. 2023. Prevalence and associated
- 716 outcomes of coinfection between SARS-CoV-2 and influenza: a systematic
- review and meta-analysis. Int J Infect Dis 136:29–36.